Thomas Bieber

48.9k total citations · 19 hit papers
479 papers, 27.7k citations indexed

About

Thomas Bieber is a scholar working on Dermatology, Immunology and Allergy and Immunology. According to data from OpenAlex, Thomas Bieber has authored 479 papers receiving a total of 27.7k indexed citations (citations by other indexed papers that have themselves been cited), including 277 papers in Dermatology, 216 papers in Immunology and Allergy and 165 papers in Immunology. Recurrent topics in Thomas Bieber's work include Dermatology and Skin Diseases (251 papers), Allergic Rhinitis and Sensitization (184 papers) and Asthma and respiratory diseases (107 papers). Thomas Bieber is often cited by papers focused on Dermatology and Skin Diseases (251 papers), Allergic Rhinitis and Sensitization (184 papers) and Asthma and respiratory diseases (107 papers). Thomas Bieber collaborates with scholars based in Germany, United States and Switzerland. Thomas Bieber's co-authors include Natalija Novak, Donald Y.M. Leung, Joerg Wenzel, Andreas Wollenberg, Kenji Kabashima, Jean‐Pierre Allam, Lisa A. Beck, Stephan Weidinger, Thomas Tüting and Alan D. Irvine and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Thomas Bieber

465 papers receiving 26.8k citations

Hit Papers

Revised nomenclature for allergy for global use: Report o... 2003 2026 2010 2018 2004 2008 2018 2014 2003 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
    2004 1.6k citations Thomas Bieber et al. profile →
  2. Atopic Dermatitis
    2008 1.4k citations Thomas Bieber profile →
  3. Atopic dermatitis
    2018 1.1k citations Stephan Weidinger, Lisa A. Beck et al. profile →
  4. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    2014 1.0k citations Lisa A. Beck, Diamant Thaçi et al. profile →
  5. Atopic dermatitis
    2003 961 citations Thomas Bieber et al. profile →
  6. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
    2018 804 citations Andreas Wollenberg, Thomas Bieber et al. Journal of the European Academy of Dermatology and Venereology profile →
  7. Atopic Dermatitis
    2010 462 citations Thomas Bieber profile →
  8. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
    2016 440 citations Emma Guttman‐Yassky, Andreas Wollenberg et al. profile →
  9. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
    2021 394 citations Thomas Bieber Nature Reviews Drug Discovery profile →
  10. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    2020 313 citations Eric L. Simpson, Andreas Wollenberg et al. profile →
  11. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
    2021 287 citations Thomas Bieber, Eric L. Simpson et al. profile →
  12. Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
    2019 258 citations Thomas Bieber Allergy profile →
  13. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    2021 250 citations Marjolein de Bruin‐Weller, Thomas Bieber et al. profile →
  14. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*
    2020 213 citations Jonathan I. Silverberg, Thomas Bieber et al. British Journal of Dermatology profile →
  15. Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
    2021 200 citations Jacob P. Thyssen, Robert Bissonnette et al. profile →
  16. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
    2020 173 citations Sonja Ständer, Thomas Bieber et al. profile →
  17. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
    2023 82 citations Pavel Kolkhir, Cezmi A. Akdiş et al. Nature Reviews Drug Discovery profile →
  18. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
    2023 72 citations Andrew Blauvelt, Jacob P. Thyssen et al. British Journal of Dermatology profile →
  19. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
    2024 66 citations Svenja Müller, Laura Maintz et al. Allergy profile →

Peers

Thomas Bieber
Comparison fields: 5 of 180
  • Dermatology 17.4k
  • Immunology and Allergy 13.9k
  • Physiology 7.6k
  • Immunology 7.3k
  • Rheumatology 4.0k
Replace Giampiero Girolomoni with:
Giampiero Girolomoni Italy
Stephen R. Durham United Kingdom
Qutayba Hamid Canada
Thomas Ruzicka Germany
Marı́a José Torres Spain
Peter Valent Austria
Enno Christophers Germany
Yong-Jun Liu United States
Lawrence B. Schwartz United States
Claus Bachert Belgium
Giampiero Girolomoni Italy View profile →
Citations per field, relative to Thomas Bieber
Thomas Bieber · 1×
Citations per year, relative to Thomas Bieber
Thomas Bieber · 1×

Countries citing papers authored by Thomas Bieber

Since Specialization
Citations

This map shows the geographic impact of Thomas Bieber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Bieber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Bieber more than expected).

Fields of papers citing papers by Thomas Bieber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Bieber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Bieber. The network helps show where Thomas Bieber may publish in the future.

Co-authorship network of co-authors of Thomas Bieber

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Bieber. A scholar is included among the top collaborators of Thomas Bieber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Bieber. Thomas Bieber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
2025 ·Dermatology and Therapy ·(unknown), Thomas Bieber, Amy S. Paller, Lisa A. Beck, Masahiro Kamata, L. Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, J.Q. Del Rosso, Linda Stein Gold, (unknown), Martín Dossenbach, Gaia Gallo, (unknown), Marta Casillas, (unknown), (unknown), Raj Chovatiya
7
2
Deciphering the Connection Between Atopic Dermatitis and Cardiovascular Diseases: Analysis of Clinical Associations and Cardiometabolic Proteins
2025 ·Allergy ·Danielle Fehr, (unknown), Laura Maintz, David Niederseer, (unknown), Anita Dreher, (unknown), Cezmi A. Akdiş, Roger Lauener, Claudio Rhyner, Claudia Traidl‐Hoffmann, Peter Schmid‐Grendelmeier, Thomas Bieber, Marie‐Charlotte Brüggen
0
3
Emerging Biologic Therapies for the Treatment of Atopic Dermatitis
2024 ·Drugs ·(unknown), Thomas Bieber, Tiago Torres
11
4
The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification
2024 ·Annals of Allergy Asthma & Immunology ·Thomas Bieber
1
5
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs breakdown →
2024 ·Allergy ·Svenja Müller, Laura Maintz, Thomas Bieber
66
6
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
2023 ·British Journal of Dermatology ·Stephan Weidinger, Thomas Bieber, Michael J. Cork, Adam Reich, Rosamund Wilson, Sonia Quaratino, Marisa Stebegg, (unknown), (unknown), John T. O’Malley, (unknown)
61
7
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials breakdown →
2023 ·British Journal of Dermatology ·Andrew Blauvelt, Jacob P. Thyssen, Emma Guttman‐Yassky, Thomas Bieber, E. Serra‐Baldrich, Eric L. Simpson, David Rosmarin, Hany Elmaraghy, (unknown), Chitra R Natalie, Zhuqing Liu, Chenjia Xu, Evangeline Pierce, (unknown), Esther García Gil, Jonathan I. Silverberg
72
8
A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis
2023 ·Journal of the European Academy of Dermatology and Venereology ·Andreas Wollenberg, Jacob P. Thyssen, Thomas Bieber, (unknown), Urs Kerkmann
8
9
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs breakdown →
2023 ·Nature Reviews Drug Discovery ·Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, Claus Bachert, Thomas Bieber, Giorgio Walter Canonica, Emma Guttman‐Yassky, Martin Metz, Joaquim Mullol, Óscar Palomares, Harald Renz, Sonja Ständer, Torsten Zuberbier, Marcus Maurer
82
10
IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis
2023 ·Allergy ·Laura Maintz, Thomas Welchowski, Nadine Herrmann, (unknown), Claudia Traidl‐Hoffmann, (unknown), Svenja Müller, Claudio Rhyner, Anita Dreher, (unknown), Matthias Schmid, Thomas Bieber
21
11
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition
2023 ·Allergy ·Eric L. Simpson, Emma Guttman‐Yassky, Lawrence F. Eichenfield, Mark Boguniewicz, Thomas Bieber, (unknown), Adriana Guana, Jonathan I. Silverberg
21
12
Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the “Flip‐Flop” phenomenon)
2023 ·Allergy ·Svenja Müller, Thomas Welchowski, Matthias Schmid, Laura Maintz, Nadine Herrmann, Dagmar Wilsmann‐Theis, (unknown), (unknown), Thomas Bieber
7
13
Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase IIa study
2022 ·Journal of the European Academy of Dermatology and Venereology ·Robert Bissonnette, William Abramovits, Étienne Saint‐Cyr Proulx, Patricia Lee, Emma Guttman‐Yassky, (unknown), Ralf Sigmund, (unknown), Thomas Bieber
34
14
Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status
2021 ·SHILAP Revista de lepidopterología ·Takashi Sakai, Nadine Herrmann, Laura Maintz, (unknown), Thomas Welchowski, Ralf A. Claus, Markus H. Gräler, Thomas Bieber
10
15
AB0042 PRECLINICAL EVALUATION OF JAK1 SELECTIVE INHIBITORS INCB039110 AND INCB054707 AS TARGETED THERAPY OF CUTANEOUS LUPUS ERYTHEMATOSUS
2019 ·Annals of the Rheumatic Diseases ·(unknown), Paul Smith, (unknown), Thomas Bieber, Joerg Wenzel
3
16
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
2019 ·American Journal of Clinical Dermatology ·Lawrence F. Eichenfield, Thomas Bieber, Lisa A. Beck, Eric L. Simpson, Diamant Thaçi, Marjolein de Bruin‐Weller, Mette Deleuran, Jonathan I. Silverberg, Carlos Ferrándiz, Regina Fölster‐Holst, Zhen Chen, Neil M.H. Graham, Gianluca Pirozzi, Bolanle Akinlade, George D. Yancopoulos, Marius Ardeleanu
114
17
F cε RI stimulation promotes the differentiation of histamine receptor 1‐expressing inflammatory macrophages
2013 ·Allergy ·Natalija Novak, Wenming Peng, Thomas Bieber, Cezmi A. Akdiş
19
18
Characterization of different courses of atopic dermatitis in adolescent and adult patients
2013 ·Allergy ·(unknown), Tobias Hagemann, Thomas Bieber, Ioanna Maria Dimitriou, Rolf Fimmers, Thomas L. Diepgen, Natalija Novak
221
19
Atopic dermatitis: a candidate for disease‐modifying strategy
2012 ·Allergy ·Thomas Bieber, Michael J. Cork, Sakari Reitamo
94
20
0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study
2006 ·Acta Dermato Venereologica ·J P Ortonne, (unknown), JC Prinz, Thomas Bieber, Morad Lahfa, Андрис Рубинс, Gottfried Wozel, G Lorette
26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giampiero Girolomoni Breakdown of academic impact, for papers by Stephen R. Durham Breakdown of academic impact, for papers by Qutayba Hamid Breakdown of academic impact, for papers by Thomas Ruzicka Breakdown of academic impact, for papers by Marı́a José Torres Breakdown of academic impact, for papers by Peter Valent Breakdown of academic impact, for papers by Enno Christophers Breakdown of academic impact, for papers by Yong-Jun Liu Breakdown of academic impact, for papers by Lawrence B. Schwartz Breakdown of academic impact, for papers by Claus Bachert
Rankless by CCL
2026